| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9236591 | Clinical Immunology | 2005 | 8 Pages |
Abstract
Prostaglandin E1 (PGE1) has therapeutic value for transplantations due to its microvascular activity. Interleukin (IL)-18, which is elevated in plasma during the acute rejection after organ transplantation, elicits the expression of intercellular adhesion molecule (ICAM)-1, B7.1, B7.2, CD40, and CD40 ligand (CD40L) on monocytes as well as the production of interferon (IFN)-γ and IL-12 and proliferation of T-cells during the human mixed lymphocyte reaction (MLR) in an in vitro model of acute rejection. In contrast, PGE1 inhibits all the adhesion molecule expression, cytokine production and T-cell proliferation in the presence of IL-18. The effects of PGE1 depend on stimulation of the IP/EP2/EP4-receptor, and thus, PGE1 might have therapeutic potential for treating acute rejection due to its immune regulatory effect.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hideo K. Takahashi, Dong Xue, Hiromi Iwagaki, Ryuji Tamura, Goutarou Katsuno, Takahito Yagi, Tadashi Yoshino, Shuji Mori, Masahiro Nishibori, Noriaki Tanaka,